Accesso Utente

Accedi con il tuo account personale per consultare i materiali riservati

  • Registrati
  • Nome utente dimenticato?
  • Password dimenticata?
Key Trials
  • HOME
  • PROGETTO
  • BOARD
  • PUBBLICAZIONI
ACCMED
  • Approfondimenti generali
  • Melanoma, Linee Guida AIOM, 2017
    Dummer R, et al. Cutaneous Melanoma: ESMO Clinical Practice Guidelines. Ann Oncol 2015; 26 (suppl 5): v126-v132
    ClinicalTrial.gov. A service of the U.S. National Institutes of Health
  • Referenze bibliografiche specifiche
  • Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006. ASCO 2016; abs. #9504
    Robert C, et al. Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment. ASCO 2017; abs. #9504
    Long GV, et al. 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. ASCO 2018; abs. #9503
© 2016 - 2018 Accademia Nazionale di Medicina - Tutti i diritti riservati
To Top